Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000517121 | SCV000612566 | uncertain significance | not specified | 2017-03-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002316467 | SCV000849679 | uncertain significance | Inborn genetic diseases | 2017-05-30 | criteria provided, single submitter | clinical testing | The p.P2145L variant (also known as c.6434C>T), located in coding exon 45 of the CACNA1A gene, results from a C to T substitution at nucleotide position 6434. The proline at codon 2145 is replaced by leucine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV000764177 | SCV000895179 | uncertain significance | Episodic ataxia type 2; Spinocerebellar ataxia type 6; Migraine, familial hemiplegic, 1; Developmental and epileptic encephalopathy, 42 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001302457 | SCV001491667 | likely benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2023-11-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004591458 | SCV005080274 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |